Author Archives: Malika Ammam, PhD

Acetylon Pharmaceuticals Publishes Mechanism Of Its Selective-Inhibition Treatment Of Sickle Cell Disease and Beta-Thalassemia

Acetylon Pharmaceuticals recently published the outcomes of its preclinical data concerning the mechanism of action of its selective inhibition based treatment of sickle cell (SC) disease/beta-thalassemia (BT). These findings, “Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2,” were published in…